John Tite

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.